Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Klotho is a naturally occurring human protein encoded by the KL gene and exists in three subfamilies: α-klotho (alpha), β-klotho (beta), and γ-klotho (gamma). The term "klotho" typically refers to α-klotho unless otherwise specified. Klotho functions as a type-I single-pass transmembrane protein with both membrane-bound and soluble forms. It acts as a co-receptor for fibroblast growth factors—α‑klotho for FGF23 and β‑klotho for FGF19/FGF21—regulating phosphate and vitamin D metabolism. Klotho modulates several molecular pathways including Wnt signaling, hypoxia-inducible factor pathway, insulin/insulin-like growth factor 1 signaling, and exerts antioxidative effects. Its deficiency is associated with accelerated aging phenotypes such as cognitive impairment, osteoporosis, arteriosclerosis, chronic kidney disease progression, cardiovascular diseases (including coronary artery disease and left ventricular hypertrophy), diabetes risk increase, muscle atrophy/frailty in aging populations as well as neurodegenerative disorders like Alzheimer’s disease. Overexpression or supplementation of klotho has been shown in animal models to extend lifespan and improve physical/cognitive health[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on klotho.